Testing protein substitute tablets for rare metabolic conditions
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests whether new protein substitute tablets are acceptable for people with certain rare metabolic disorders. Participants will replace their usual protein substitute with the study tablets for 7 days to see if they can tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these rare metabolic conditions: Tyrosinaemia type I, II, III, Alkaptonuria, Homocystinuria, or MSUD.
- You already take a special protein substitute for your condition and are willing to try a new tablet form for 7 days.
- You are 7 years old or older.
- You have not taken antibiotics in the last 2 weeks.
- You are not currently participating in other clinical trials.
- Your parent or guardian agrees to sign a consent form if you are a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new microtablet form of protein substitute for people with PKU. It aims to see if taking these tablets helps you meet your protein needs while staying on your PKU diet.
This trial tests a new powdered protein substitute (GMP) for people with PKU or tyrosinemia. It aims to see if it is a safe and effective option to help manage their condition.
This study tests a new liquid form of two key supplements (valine and isoleucine) for children with maple syrup urine disease (MSUD). It aims to make it easier to take these supplements, which help manage the condition.
This study tests a new app called MyRareDiet for people with certain metabolic disorders. It helps you track your diet more easily so you can stick to your protein and calorie goals.
This trial tests a new pill called JNT-517 to see if it can lower high blood phenylalanine (Phe) levels in people with PKU. You may be a good fit if you have PKU, are at least 18, and can stick to a steady diet.
This trial tests an investigational drug (AG-181) for people with PKU who have a specific genetic change (R408W mutation). It aims to check if the drug is safe and how it works in your body.
Hear when a new Tyrosinemia, Type I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.